[1] Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6 (9), 688−701.
[2] Haag, R.; Kratz, F. Polymer therapeutics: Concepts and applications. Angew. Chem., Int. Ed. 2006, 45 (8), 1198−215.
[3] de Bono, J. S.; Ashworth, A. Translating cancer research into targeted therapeutics. Nature 2010, 467 (7315), 543−9.
[4] Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discovery 2008, 7 (9), 771−82.
[5] Mullen, D. G.; Fang, M.; Desai, A.; Baker, J. R.; Orr, B. G.; Holl, M. M. B. A Quantitative Assessment of Nanoparticle-Ligand Distributions: Implications for Targeted Drug and Imaging Delivery in Dendrimer Conjugates. ACS Nano 2010, 4 (2), 657−70.
[6] Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A. K.; Thomas, T.; Mule, J.; Baker, J. R. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 2002, 19 (9), 1310−6.
[7] Kukowska-Latallo, J. F.; Candido, K. A.; Cao, Z.; Nigavekar, S. S.; Majoros, I. J.; Thomas, T. P.; Balogh, L. P.; Khan, M. K.; Baker, J. R., Jr. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005, 65 (12), 5317−24.
[8] Majoros, I. J.; Thomas, T. P.; Mehta, C. B.; Baker, J. R. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem. 2005, 48 (19), 5892−9.
[9] Thomas, T. P.; Majoros, I. J.; Kotlyar, A.; Kukowska-Latallo, J. F.; Bielinska, A.; Myc, A.; Baker, J. R., Jr. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J. Med. Chem. 2005, 48 (10), 3729−35.
[10] Majoros, I. J.; Williams, C. R.; Becker, A.; Baker, J. R., Jr. Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. Wiley Interdiscip. Rev.: Nanomed. anobiotechnol. 2009, 1 (5), 502−10.
[11] Gillies, E. R.; Frechet, J. M. J. Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today 2005, 10 (1), 35−43.
[12] Lim, P.B., J. Wang, J., Ng, S. C., Chew, C. H., and M. Gan, L., “A bicontinuous microemulsion route to zinc oxide powder,” Ceramics International, 1998, vol. 24, no. 3, pp. 205–209.
[13] M. Inoguchi, Suzuki, M.K., Kageyama, Takagi, K.H., and Sakabe, Y., “Monodispersed and well-crystallized zinc oxide nanoparticles fabricated by microemulsion method,” Journal of the American Ceramic Society, 2008, vol. 91, no. 12, pp. 3850–3855.
[14] Hingorani, Pillai, Kumar, S.V.P., Multani,M. S. and Shah, D. O., “Microemulsion mediated synthesis of zinc-oxide nanoparticles for varistor studies,” Materials Research Bulletin, 1993, vol. 28, no. 12, pp. 1303–1310.
[15] Christensen FM, Johnston HJ, Stone V, Aitken RJ, Hankin S, Peters S, et al. Nano-silver e feasibility and challenges for human health risk assessment based on open literature. Nanotoxicology 2010;4:284e95.
[16] Stensberg MC, Wei Q, McLamore ES, Porterfield DM, Wei A, Sepulveda MS. Toxicological studies on silver nanoparticles: challenges and opportunities in assessment, monitoring and imaging. Nanomedicine 2011;6:879e98.
[17] Pronk MEJ, Wijnhoven SWP, Bleeker EAJ, Heugens EHW, Peijnenburg WJGM, Luttik R, et al. Nanomaterials under REACH. Nanosilver as a case study. Bilthoven, The Netherlands: RIVM.report601780003.Availablefrom:http://www.rivm.nl/bibliotheek/rapporten/601780003.html; 2009.
[18] De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJAM, Geertsma RE. Particle size dependent organ distribution of gold nanoparticles after intervenous administration. Biomaterials 2008;29:1912e9.
[19] Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander CW, et al. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 2010;31:8350e61.
[20] Lankveld DPK, Rayavarapu RG, Krystek P, Oomen AG, Verharen HW, Van Leeuwen TG, et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine 2011;6:339 e49.
[21] A. FULIAŞ, C. POPOIU, G. VLASE, T. VLASE, D. ONEŢIU, G. SĂVOIU, SIMU, C. PĂTRUŢESCU, GHEORGHE ILIA , I. LEDEŢI University of Medicine and Pharmacy “Victor Babeş”, Faculty of Digest J. Nanomater. and Biostruct. 2014, 9, 1, 93 – 98.
[22] Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, et al. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. J Control Release , 2014, 174: 195-201.
[23] Tosi G, Vilella A, Chhabra R, Schmeisser MJ, Boeckers TM, et al. Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transportJ Control Release, 1997, 177, (2014), 96-107.
[24] Van Meurs JBJ, van Lent PLEM, Singer II, Bayne EK, van de Loo FAJ, van den Berg WB. (1998). lnterleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigeninduced arthritis. Arthritis Rheum; 41:647-656.
[25] Zhu, L.; Wei, W.; Zheng, Y. Q. and Jia, X.Y.(2005). Effects and mechanisms of total glucosides of paeony on joint damage in rat collagen-induced arthritis. Inflammation Research. 54 (5), 211-20.
[26] Adkar, P. P. ; Dongare,A.; Ambavade S. D, & Bhaskar, V. H. (2014). Effect of Trapa bispinosa on HDAC Level in Animal Tissues for its Anti-arthritic Activity. Research Journal of Pharmaceutical, Biological and Chemical Sciences ; 5 (4) : 1409 - 1412.
[27] Thiyagarajan, V.; P. Muthusamy, N.;Jayshree, R. & Vijaya, B.(2015). Evaluation of Anti-arthritic potential of Adansonia digitata seed extract. International Journal of Multidisciplinary Research and Development; 2(4): 548-554.
[28] Daniel, C.; McGillicuddy, K. H. Shah; Ryan P.; Larry A. and Jonathan A.(2007) How sensitive is the synovial fluid white blood cell count in diagnosing septic arthritis? The American Journal of Emergency Medicine; 25(7): 749-752.
[29] Mohanan, D. ; Slutter, B.; Henriksen-Lacey, M. ; Jiskoot, W. ; Bouwstra, J.A. ; Perrie, Y.; Kundig, T.M.; Gander, B. & Johansen, P. (2010).Administration routes affect the quality of immune responses: A crosssectional evaluation of particulate antigen-delivery systems. J Control Release.; 147 : 342 - 349 .
[30] Liu , Y.; Jiao, F.; Qiu, Y.; Li, W.; Lao, F.; Zhou, G. ; Sun, B.; Xing, G. ; Dong, J. ;Zhao, Y.; Chai, Z.& Chen, C. (2009) .The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity. Biomaterials; 30 : 3934 - 3945 .
[31] Tan, Y. ; Li, S. ; Pitt, B. R.& Huang, L. (1999) .The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene The.r.; 10: 2153-2161.
[32] Sharma, A.& Arora, S. (2012 ). Formulation and In Vitro evaluation of ufasomes for dermal administration of methotrexate. ISRN Pharmaceutics; 12: 174-182 .
[33] Grund , S. ; Bauer , M. & Fischer , D. (2011).Polymers in Drug Delivery-State of the Art and Future Trends. Adv. Eng. Mater., 13: 61-87.
[34] Roy , K. ; Kanwar, R. K. & Kanwar, J. R. (2015). Molecular targets in arthritis and recent trends in nanotherapy. International Journal of Nanomedicine ;10 :5407-5420.
[35] Wani, U. ; Rashid , M. ; Kumar, M. ; Chaudhary, S. ; Kumar, P.& Mishra, N.(2014).Trgeting Aspects Of Nanogel. International Journal Of Pharmaceutical And Nanotechnology ; 7(4) : 2612-2631.
[36] Rohr MK, Mikuls TR, Cohen SB, Thorne CJ, O’Dell JR. The underuse of methotrexate in the treatment of RA: a national analysis of prescribing practices in the U.S. Arthritis Care Res (Hoboken). Epub2016 Nov 18.)
[37] Yang X, Chang Y, Wei W. Endothelial dysfunction and inflammation:immunity in rheumatoid arthritis. Mediators Inflamm. 2016;2016:6813016.)
[38] Voloshyna I, Seshadri S, Anwar K, Littlefield MJ, Belilos E, Carsons SE, et al.Infliximab reverses suppression of cholesterol efflux proteins by TNF-α: apossible mechanism for modulation of atherogenesis. Biomed Res Int.2014;2014:8.)
[39] Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/ macrophages. Arthritis Rheum. 2008;58(12):3675–83.
[40] (Ronda N, Greco D, Adorni MP, Zimetti F, Favari E, Hjeltnes G, et al. Newly identified anti atherosclerotic activity of methotrexate and adalimumab:complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol. 2015;67(5):1155–64.)
[41] Ohya N, Yamada H, Hama N, Kikukawa T, Ichikawa Y.Methotrexate inhibits IL-6 and matrix metalloproteinase-2production by mixed synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999;42:S196.
[42] Fagerli KM et al., The role of methotrexate co-medication inTNF-inhibitor treatment in patients with psoriaticarthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73:132–137.
[43] Olsen, N. J., Spurlock, C. F. &Aune, T. M. Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis. Res. Ther. 16, R17(2014).
[44] Rafael Segal, Michael Yaron, and Boris Tartakovsky. Methotrexate: Mechanism of Action in Rheumatoid Arthritis. Seminars in Arthritis and Rheumafism, Vol20, No 3 (December), 1990: pp 190- 199.
[45] Ounissi-Benkalha et al.,In vitro effects of 2 anti rheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis.J Rheumatol. 1996 Jan;23(1):16-23.
[46] Eijsbouts et al., Effects of naproxen and sulphasalazine or methotrexate on hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2011; 29: 35-42.
[47] Martin Conda-Sheridan et al., Esterase -Activated Release of Naproxen from Supramolecular Nanofibres. ChemCommun (Camb). 2014 November 18; 50(89): 13757–13760.
[48] Clinton F. Stewart et al., Coadministration of naproxen andlow-dose methotrexate in patients withrheumatoid arthritis. CLIN PHARIVIACOL THER 1990;47:540-6.